Premium
Outcomes of TP53 ‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
Author(s) -
Badar Talha,
Atallah Ehab,
Shallis Rory M.,
Goldberg Aaron D.,
Patel Anand,
Abaza Yasmin,
Bewersdorf Jan P.,
Saliba Antoine N.,
Correia Guilherme Sacchi De Camargo,
Murthy Guru,
Duvall Adam,
Burkart Madelyn,
Stahl Maximilian,
Liu Yuanhang,
Dinner Shira,
Palmisiano Neil,
Litzow Mark R.,
Foran James M.
Publication year - 2022
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26546
Subject(s) - medicine , cytarabine , oncology , azacitidine , venetoclax , myeloid leukemia , transplantation , chemotherapy , daunorubicin , clinical trial , induction chemotherapy , leukemia , biochemistry , gene expression , chemistry , chronic lymphocytic leukemia , dna methylation , gene